Use of poziotinib for the treatment of cancers with nrg1 fusions
AssigneeBoard of Regents, The University of Texas System
InventorsJohn HEYMACH, Jacqulyne ROBICHAUX
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of selecting cancer patients for treatment with poziotinib as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with poziotinib alone or in combination with HER2/HER3 targeting antibodies.
Claims54
A method of treating a patient having a cancer, the method comprising administering to the patient a therapeutically effective amount of poziotinib, wherein the cancer has an NRG1 fusion.
A method of treating a patient having a cancer, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion;
- (b) selecting or having selected the patient for treatment with poziotinib when the patient's cancer has an NRG1 fusion;
- and (c) administering or having administered to the selected patient a therapeutically effective amount of poziotinib.
A method of selecting a patient having a cancer for treatment with poziotinib, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion;
- (b) selecting or having selected the patient for treatment with poziotinib when the patient's cancer has an NRG1 fusion.
A method of treating a patient having a cancer, the method comprising administering to the patient a combined therapeutically effective amount of poziotinib and a HER2/HER3 targeting antibody, wherein the cancer has an NRG1 fusion.
A method of treating a patient having a cancer, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion;
- (b) selecting or having selected the patient for treatment with poziotinib and a HER2/HER3 targeting antibody when the patient's cancer has an NRG1 fusion;
- and (c) administering or having administered to the selected patient a combined therapeutically effective amount of poziotinib and HER2/HER3 targeting antibody.
A method of selecting a patient having a cancer for treatment with poziotinib and HER2/HER3 targeting antibody, the method comprising (a) determining or having determined whether the patient's cancer has an NRG1 fusion;
- (b) selecting or having selected the patient for treatment with poziotinib and a HER2/HER3 targeting antibody when the patient's cancer has an NRG1 fusion.
Dependencies are inferred from the claim text.